ANVS — Annovis Bio, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1477845 ·
Last close
$0.74
Market Cap
$31.97M
52W High
$5.50
52W Low
$0.62
ADV30
2,560,739
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -14,377,712 | -14,820,815 | 22,037,091 | 18,728,945 | 26,291,709 |
| Mar 2026 | 0 | — | -18,012,182 | -17,606,382 | 16,243,703 | 14,219,081 | 13,117,645 |
| Dec 2025 | 0 | — | -9,706,149 | -9,834,412 | 21,081,625 | 19,532,338 | 4,230,375 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,339,894
Investing CF
—
Financing CF
$44,938,553
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-196,130,856
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-49,531,018
Pretax Income TTM
$-49,524,267
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,695,258 | -28,854,197 | 21,081,625 | 4,230,375 | 16,851,250 | -25,619,703 |
| Dec 2024 | 0 | -26,694,928 | -24,590,375 | 13,925,633 | 4,617,987 | 9,307,646 | -21,894,604 |
| Dec 2023 | 0 | -45,035,011 | -56,204,313 | 10,208,264 | 17,959,110 | -7,750,846 | -39,967,304 |
| Dec 2022 | 0 | -25,511,279 | -25,328,567 | 36,022,069 | 7,698,539 | 28,323,530 | -17,312,934 |
TTM Snapshot
Revenues TTM
$618,087
NetIncome TTM
$-49,524,267
OpCashFlow TTM
—
Assets (Latest)
$22,037,091
Forward EPS
$-0.86
Max Pain — expiry 2026-11-27 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.84 · call volume: 670 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TELO | Telomir Pharmaceuticals, Inc. | $31.17M | $0.42 | — |
| RNTX | Rein Therapeutics, Inc. | $30.75M | $0.36 | — |
| NXTC | NextCure, Inc. | $30.68M | $6.70 | — |
| BCTX | BriaCell Therapeutics Corp. | $30.65M | $3.51 | — |
| NSRX | Nasus Pharma Ltd | $30.57M | $2.61 | — |
News headlines (Yahoo Finance, 1h cache)
Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study
2026-11-17 13:00 · Yahoo
Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
2026-11-13 13:00 · Yahoo
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
2026-11-12 13:00 · Yahoo
Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
2026-11-09 12:00 · Yahoo
Annovis Announces Pricing of $21.0 Million Public Offering
2026-11-05 13:05 · Yahoo
Annovis Announces Launch of Proposed Public Offering
2026-11-04 21:07 · Yahoo
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
2026-10-30 21:00 · Yahoo
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
2026-10-29 12:00 · Yahoo
Annovis to Attend the CTAD 2026 with Three Presentations
2026-10-22 12:00 · Yahoo
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-09-08 13:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.